Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$31.49 USD
-0.18 (-0.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $31.48 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AGIO 31.49 -0.18(-0.57%)
Will AGIO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates
Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline
Other News for AGIO
Agios Pharma (AGIO) Receives a Buy from Piper Sandler
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report